These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34695732)

  • 1. The development of modulators for lysophosphatidic acid receptors: A comprehensive review.
    Liu W; Hopkins AM; Hou J
    Bioorg Chem; 2021 Dec; 117():105386. PubMed ID: 34695732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials.
    Lin YH; Lin YC; Chen CC
    Cells; 2021 Jun; 10(7):. PubMed ID: 34209775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor.
    Im DS
    Arch Pharm Res; 2012 Jun; 35(6):945-8. PubMed ID: 22870802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development.
    Meduri B; Pujar GV; Durai Ananda Kumar T; Akshatha HS; Sethu AK; Singh M; Kanagarla A; Mathew B
    Eur J Med Chem; 2021 Oct; 222():113574. PubMed ID: 34126459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse.
    Ledein L; Léger B; Dees C; Beyer C; Distler A; Vettori S; Boukaiba R; Bidouard JP; Schaefer M; Pernerstorfer J; Ruetten H; Jagerschmidt A; Janiak P; Distler JHW; Distler O; Illiano S
    Br J Pharmacol; 2020 Sep; 177(18):4296-4309. PubMed ID: 32627178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Druggable Lysophospholipid Signaling Pathways.
    Yanagida K; Valentine WJ
    Adv Exp Med Biol; 2020; 1274():137-176. PubMed ID: 32894510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain.
    Velasco M; O'Sullivan C; Sheridan GK
    Neuropharmacology; 2017 Feb; 113(Pt B):608-617. PubMed ID: 27059127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of anticancer lysophosphatidic acid agonists and antagonists.
    Parrill AL
    Future Med Chem; 2014 May; 6(8):871-83. PubMed ID: 24962280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophospholipid receptors in drug discovery.
    Kihara Y; Mizuno H; Chun J
    Exp Cell Res; 2015 May; 333(2):171-177. PubMed ID: 25499971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells.
    Ren Y; Guo L; Tang X; Apparsundaram S; Kitson C; Deguzman J; Fuentes ME; Coyle L; Majmudar R; Allard J; Truitt T; Hamid R; Chen Y; Qian Y; Budd DC
    Microvasc Res; 2013 Jan; 85():59-67. PubMed ID: 23084965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox.
    Llona-Minguez S; Ghassemian A; Helleday T
    Prog Lipid Res; 2015 Apr; 58():51-75. PubMed ID: 25704399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LPA
    Decato BE; Leeming DJ; Sand JMB; Fischer A; Du S; Palmer SM; Karsdal M; Luo Y; Minnich A
    Respir Res; 2022 Mar; 23(1):61. PubMed ID: 35303880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Edg family LPA receptors: the cutting edge of LPA research.
    Yanagida K; Ishii S
    J Biochem; 2011 Sep; 150(3):223-32. PubMed ID: 21746769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
    Budd DC; Qian Y
    Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA
    Taniguchi R; Inoue A; Sayama M; Uwamizu A; Yamashita K; Hirata K; Yoshida M; Tanaka Y; Kato HE; Nakada-Nakura Y; Otani Y; Nishizawa T; Doi T; Ohwada T; Ishitani R; Aoki J; Nureki O
    Nature; 2017 Aug; 548(7667):356-360. PubMed ID: 28792932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease.
    Zhou Y; Little PJ; Ta HT; Xu S; Kamato D
    Pharmacol Ther; 2019 Dec; 204():107404. PubMed ID: 31472182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LPA receptor signaling as a therapeutic target for radical treatment of neuropathic pain and fibromyalgia.
    Ueda H
    Pain Manag; 2020 Jan; 10(1):43-53. PubMed ID: 31852400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
    Palmer SM; Snyder L; Todd JL; Soule B; Christian R; Anstrom K; Luo Y; Gagnon R; Rosen G
    Chest; 2018 Nov; 154(5):1061-1069. PubMed ID: 30201408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysophosphatidic acid and its receptor LPA
    Srikanth M; Chew WS; Hind T; Lim SM; Hay NWJ; Lee JHM; Rivera R; Chun J; Ong WY; Herr DR
    Eur J Pharmacol; 2018 Dec; 841():49-56. PubMed ID: 30321532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of hepatobiliary toxicity of the LPA
    Gill MW; Murphy BJ; Cheng PTW; Sivaraman L; Davis M; Lehman-McKeeman L
    Toxicol Appl Pharmacol; 2022 Mar; 438():115885. PubMed ID: 35090952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.